Introduction The therapeutic armamentarium for managing Crohn's disease (CD) has
expanded significantly in recent decades. Several biologics with three different mechanisms …

A cure for Crohn's disease (CD), a chronic inflammatory disease of the gastrointestinal tract
of unknown etiology, is not available, so patients require lifelong management to keep …

Background: Anti-tumour necrosis factor (TNF) agents are effective in Crohn's disease (CD),
but some patients lose responsiveness and require alternative biologic therapy. Until …

Background Ustekinumab and vedolizumab are both effective for treating Crohn's disease
(CD). However, no head-to-head trials have been conducted thus far. We aimed to compare …

Abstract Background and Aims This study compares the effectiveness of different biologic
therapies and sequences in patients with inflammatory bowel disease [IBD] using real-world …

METHODS: We conducted a retrospective cohort study using longitudinal claims data from a
large US insurer (Anthem, Inc.). We identified patients with CD initiating vedolizumab or …

Background No study has performed a face-to-face comparison of biologics after the failure
of the first anti-TNF agent in patients with Crohn's disease (CD). The aim of the study was to …

Background Several biologics are available for the treatment of moderate to severe Crohn's
disease, but data to optimize their use are scarce. Vedolizumab (VDZ) is a gut‐selective anti …

Introduction Expeditious initiation of biologic therapy is important in patients with
inflammatory bowel disease (IBD). However, initiation of biologics in the outpatient setting …

Background: Treatment with antitumor necrosis factor alpha (anti-TNF-α) is safe and
effective as first-line therapy; however, its efficacy is limited due to primary nonresponse …